By attaching to this protein’s DNA binding site, EG1 can phenocopy a PAX2 mutation to prevent PAX2–DNA interactions in vitro and in ex vivo kidney organ cultures; consequently, this could be beneficial in the future for the treatment of many urogenital cancers and renal malignancies. The gene discussed is PAX2; the disease is urogenital neoplasm.